ALKS (Alkermes PLC) Net earnings per one share for the last twelve months

Alkermes plc payout stability relies on patent expiration dates and government insurance. This chart of EPS YoY ttm growth rates confirms the model's resilience, where the -100.60 value serves as a baseline reliability indicator. The company's advantage lies in inelastic demand and unique drug delivery methods, while an active R&D pipeline in oncology and psychiatry ensures future growth.

alkermes.com (ALKS) Net earnings per share (EPS TTM): for the period 02/11/2024 - 11/15/2026

Alkermes Corp - analytical breakdowns and key metrics (ALKS)

- market price and analyst price targets:

Market Chart Alkermes Inc.|ALKS - Consensus Target

- business market valuation indicators:

Market Value Alkermes Inc.|ALKS - Enterprise Value

- company book value details:

Accounting Value per Share Alkermes|ALKS - Book Capitalization|Market Value to Book Value alkermes.com|ALKS - Aggregate Company Assets

- company total debt and liquidity indicators:

- earnings and market multiples details:

ALKS - Company Net Income|Expected Net Income Alkermes plc|ALKS - Price to Earnings Ratio|Projected Price to Earnings Alkermes Inc.|ALKS - PEG Multiple|Company Value to EBITDA Alkermes Corp|ALKS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Alkermes|ALKS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months alkermes.com|ALKS - Earnings per share growth in current year|Net earnings per share change forecast for next year Alkermes plc

- sales and revenue indicators:

ALKS - Company Revenue|Company Projected Revenue Alkermes|ALKS - P/S Multiple|Forward Price-to-Revenue Multiple Alkermes Inc.|ALKS - Sales Growth YoY (TTM)

Initial company analysis:Alkermes PLC - ALKS

This indicator measures the dynamics of net earnings per share over the last twelve months relative to the same period last year, reflecting the actual growth rate of return on equity. By comparing the history of EPS YoY (TTM) percentage changes with the quotes of Alkermes plc (ALKS), an investor assesses the efficiency of cost management, including strict compliance with environmental regulations and energy saving at pharmaceutical production facilities.

Competitor analysis

Net earnings per share for the last four quarters Avadel Pharma AVDL|ATAI (atai.life) - Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months GH Research Corp (GHRS)|MNMD (mindmed.co) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months COMPASS Pathways plc (CMPS)|Net earnings per share (EPS TTM) LBRX|DRUG (Bright Minds Bio) - Earnings per share for the trailing year|Earnings per share for the last twelve months vandapharma.com VNDA|Cybin Corp (CYBN) - Net earnings per one share for the last twelve months|Alto Neuroscience Corp - Net earnings per share (EPS TTM)|NRXP (nrxpharma.com) - Earnings per share for the last 12 months|CING: Net earnings per share (EPS TTM)|SILO - Net earnings per share for the last four quarters|CPHI (China Pharma Holdings, Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Clearmind Medicine Inc. CMND|Earnings per share for the last twelve months Psyence Biomedical (PBM)|Net earnings per share for the last four quarters scisparc.com|Earnings per share for the last twelve months Seelos Therapeutics Inc SEEL|Net earnings per share (EPS TTM) virpaxpharma.com VRPX|Karuna Therapeutics Inc - Net earnings per share (EPS TTM)